That’s right — organic chemistry.You thought you were done with orgo. Admit it, the first thing you did after reading the headline of this column was sprint to your safe spot. You were so traumatized by the mere mention of organic chemistry that you pu…
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,…